Tianjin First Central Hospital

Founded in 1942, Tianjin First Central Hospital is a Tianjin Medical Center integrating clinical care, education, research, prevention, healthcare, and rehabilitation, and a National Regional Medical Center under construction. As a national-level major epidemic rescue base and major infectious disease prevention base, the hospital ranks among China's Top 100 Hospitals and National Trustworthy Demonstration Hospitals, distinguished by its three flagship specialties: organ transplantation, emergency medicine, and otolaryngology head and neck surgery. The hospital operates two clinical campuses—Fukang and Shuixi—plus a research and teaching campus, with 3,200 beds and over 4,000 employees, including 45 doctoral supervisors and 215 master's supervisors. It houses 8 national key clinical specialties, 12 Tianjin key medical disciplines, and 16 Tianjin key clinical specialties, along with 6 municipal research institutes. The Organ Transplantation Center is nationally renowned, qualified to perform heart, liver, kidney, pancreas, lung, and small intestine transplantations. A landmark research achievement led by the hospital resulted in the world's first chemically reprogrammed induced pluripotent stem cell-differentiated islet transplantation for type 1 diabetes, published in the top journal Cell (Best Paper of 2024) and recognized as a National Health Science Highlight. The International Medical Center, with 52 beds, provides integrated services encompassing geriatric and comprehensive disease treatment, preventive healthcare, and health management for foreign guests and VIP patients, serving as a key foreign-related medical service window in Tianjin.